Beckman Coulter Inc Cytomics FC 500 Flow Cytometry System with CXP Software Versions 2.0 & 2.1 Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Cytomics FC 500 Flow Cytometry System with CXP Software Versions 2.0 & 2.1
Brand
Beckman Coulter Inc
Lot Codes / Batch Numbers
Part Numbers: 722645 Software Kit, CXP version 2.1 New User, 723113 Software Kit, CXP version 2.1 Upgrade, 629637 Software Kit, CXP version 2.0 New User, 629636 Software Kit, CXP version 2.0 Upgrade, 626553 TN, FC500 WITH UPS, 6605627 TN, 5 CLR, FC500 (IOOV), 6605628 TN, 5 CLR, FC500 (120V), 6605629 TN, 5 CLR, FC500 (220V), 6605630 TN, 5 CLR, FC500 (240V)
Products Sold
Part Numbers: 722645 Software Kit; CXP version 2.1 New User; 723113 Software Kit; CXP version 2.1 Upgrade; 629637 Software Kit; CXP version 2.0 New User; 629636 Software Kit; CXP version 2.0 Upgrade; 626553 TN; FC500 WITH UPS; 6605627 TN; 5 CLR, FC500 (IOOV); 6605628 TN; 5 CLR, FC500 (120V); 6605629 TN; 5 CLR, FC500 (220V); 6605630 TN;5 CLR, FC500 (240V)
Beckman Coulter Inc is recalling Cytomics FC 500 Flow Cytometry System with CXP Software Versions 2.0 & 2.1 due to Mis-identification-If a panel or protocol is added to an existing worklist but the tube location is not specified, the CXP Acquisition software will r. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Mis-identification-If a panel or protocol is added to an existing worklist but the tube location is not specified, the CXP Acquisition software will run the last specified tube through the remaining protocols and will generate results and printouts of these runs leading to a Mis-Identification condition.
Recommended Action
Per FDA guidance
Customer letter -- A Product Corrective Action (PCA) letter was sent the week of July 24, 2006 to all accounts that have FC500 with CXP Software 2.0 and 2.1 to inform them that a potential sample misidentification may occur when running a Work list with missing tube Location(s) in Automatic MCL mode. The letter outlines actions to be taken to avoid mis-identification of patient results.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026